| Literature DB >> 29987817 |
Irene C Turnbull1, Joshua Mayourian1, Jack F Murphy1, Francesca Stillitano1, Delaine K Ceholski1, Kevin D Costa2.
Abstract
The lack of biomimetic in vitro models of the human heart has posed a critical barrier to progress in the field of modeling cardiac disease. Human engineered cardiac tissues (hECTs)-autonomous, beating structures that recapitulate key aspects of native cardiac muscle physiology-offer an attractive alternative to traditional in vitro models. Here we describe the use of hECTs to advance our understanding and modeling of cardiac diseases in order to test therapeutic interventions, with a focus on contractile dysfunction in the setting of inherited and acquired forms of cardiomyopathies. Four major procedures are discussed in this chapter: (1) preparation of hECTs from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) on single-tissue and multitissue bioreactors; (2) data acquisition of hECT contractile function on both of these platforms; (3) hECT modeling of hereditary phospholamban-R14 deletion-dilated cardiomyopathy; and (4) cryo-injury and doxorubicin-induced hECT models of acquired cardiomyopathy.Entities:
Keywords: Acquired cardiomyopathy; Contractility; Genetic cardiomyopathy; Models of disease; Stem cells; Tissue engineering
Mesh:
Substances:
Year: 2018 PMID: 29987817 PMCID: PMC6561092 DOI: 10.1007/978-1-4939-8597-5_11
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745